Myelodysplastic Syndromes, Myeloproliferative Disorder, Pulmonary Hypertension
Conditions
Brief summary
Myelodysplastic and myeloproliferative Disease represent conditions with increased risk for pulmonary hypertension. However, the exact prevalence of pulmonary hypertension in these conditions is not known. The effects of pulmonary hypertension on the clinical picture and the symptoms of patients in these conditions needs also further exploration. This exploratory study is designed to describe the prevalence of pulmonary hypertension in the population with such hematologic diseases, and the stages of pulmonary hypertension as well its effect on exercise capacity at time of diagnosis.
Detailed description
For early recognition of pulmonary hypertension exercise doppler echocardiography will be used in all patients. Patients with elevated pulmonary arterial pressure at rest or during exercise (estimated by echocardiography), or with decreased exercise capacity (as a potential sign of pulmonary hypertension) are advised to undergo right heart catheterisation. Cardiopulmonary exercise testing and six-minute walk distance measurement are performed to measure exercise capacity. The described work-up of patients allows precise and objective hemodynamic and clinical evaluation.
Interventions
OTHERechocardiography, right heart catheterisation
at each patient an echocardiography will be performed at rest and during exercise. For the evaluation of exercise capacity, cardiopulmonary exercise testing and six-minute walk is performed. Right heart catheterisation is recommended to those with suspected pulmonary hypertension.
Sponsors
Medical University of Graz
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 95 Years
Healthy volunteers
No
Inclusion criteria
* myelodysplastic disease or myeloproliferative diseases
Exclusion criteria
* known pulmonary hypertension * relevant pulmonary disease * relevant left cardiac or valvular disease * recent major operations * recent changes in medications * relevant anaemia * inability to exercise
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| mean pulmonary arterial pressure at rest and during exercise | at baseline and after 1 year |
Secondary
| Measure | Time frame |
|---|---|
| exercise capacity | at baseline and after 1 year |
Countries
Austria
Outcome results
None listed